{
"code": "SASDW54",
"status": "Published",
"type_of_curve": "SEC-SAS",
"angular_unit": "1/A",
"project": {
"title": " IgG4\n and IgG1\n undergo common acid‐induced compaction into an alternatively folded state",
"publication": {
"title": " IgG4\n and IgG1\n undergo common acid‐induced compaction into an alternatively folded state",
"author_list": "Imamura H, Honda S",
"journal": "FEBS Letters",
"doi": "10.1002/1873-3468.70031",
"pmid": null,
"published_date": "2025 Mar 17"
},
"status": "released",
"submitted_date": "2024-12-19",
"released_date": "2025-03-17"
},
"pddf_data": "https://www.sasbdb.org/media/p_of_R_files/SASDW54.out",
"intensities_data": "https://www.sasbdb.org/media/intensities_files/SASDW54.dat",
"intensities_log_plot": "https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_dat_img.png",
"intensities_kratky_plot": "https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_kratky_img.png",
"pddf_plot": "https://www.sasbdb.org/media/p_of_R_files/pofr_images/SASDW54_pofr_img.png",
"intensities_guinier_plot": "https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_guinier_img.png",
"sascif_data": "https://www.sasbdb.org/media/sascif/sascif_files/SASDW54.sascif",
"experiment": {
"instrument": {
"detector": {
"type": null,
"name": "Pilatus3 2M",
"resolution": 0.172
},
"name": "Photon Factory (PF), High Energy Accelerator Research Organization (KEK)",
"city": "Tsukuba",
"country": "Japan",
"beamline_name": "BL-10C",
"beam_geometry": null,
"type_of_source": "X-ray synchrotron",
"point_source": null,
"line_collimation": null,
"sample_path_length": null,
"line_collimation_slitlength": null,
"line_collimation_integrationwidth": null,
"xray_energy": null,
"beam_profile_ah": null,
"beam_profile_al": null
},
"sample": {
"molecule": [
{
"long_name": "humanized immunoglobulin G1 monoclonal antibody (trastuzumab)",
"short_name": "IgG1",
"sequence": ">Heavy chain 1\r\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\r\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\r\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\r\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG\r\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\r\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE\r\nMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\r\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\r\n>Heavy chain 2\r\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\r\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\r\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\r\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG\r\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\r\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE\r\nMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\r\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\r\n>Light chain 1\r\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\r\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\r\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\r\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC\r\n>Light chain 2\r\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\r\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\r\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\r\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
"organism": "Mouse/human",
"uniprot_code": null,
"uniprot_range_first": null,
"uniprot_range_last": null,
"oligomerization": "monomer",
"molecular_type": "protein",
"uniprot_sequence": "",
"mw": 148.0,
"total_mw": 148.0,
"number_molecules": 1,
"complex_state": false,
"deuteration": null,
"molecule_source": "biological",
"molecule_description": "DrugBank ID: DB00072\r\nhttps://go.drugbank.com/drugs/DB00072\r\nHeavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf)."
}
],
"buffer": {
"name": "100 mM glycine-HCl, 200 mM NaCl",
"concentration_unit": null,
"comment": null,
"additive": null,
"concentration": null,
"pka": null,
"ph": 2.0,
"deuteration": null
},
"purity_method": null,
"name": "Immunoglobulin G1 (pH 2, 0.2 M NaCl), SEC-SAXS data",
"ext_coefficient": null,
"contrast": null,
"specific_vol": null,
"dry_vol": null,
"absorbption": null,
"deuteration": null,
"mixture": null
},
"contributor": [
{
"affiliation": [
{
"short_name": null,
"address": null,
"full_name": "Toyama Prefectural University",
"webpage": null
}
],
"contributor_name": "Hiroshi",
"contributor_surname": "Imamura",
"orcid": "https://orcid.org/0000-0001-8924-747X"
}
],
"concentration_method": null,
"concentration_unit": null,
"date": "2023-05-20",
"storage_temperature": 4.0,
"cell_temperature": 25.0,
"exposure_time": 20.0,
"number_of_frames": 13,
"wavelength": 0.15,
"sample_detector_distance": 2.0,
"concentration_min": null,
"concentration_max": 10.0,
"sample_volume": 400.0,
"flow_rate": 0.2,
"s_min": 0.044,
"s_max": 2.731,
"total_exposure_time": null,
"seccolumn": 1
},
"fits": [],
"estimated_volume_method": null,
"pddf_software": "ATSAS GNOM",
"pddf_software_version": "5.0",
"i0_calibration_standard": null,
"description": "DrugBank ID: DB00072 https://go.drugbank.com/drugs/DB00072. Heavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf).",
"experiment_description": "Synchrotron SAXS data from solutions of Immunoglobulin G in 100 mM glycine-HCl, 200 mM NaCl, pH 2 were collected on the BL-10C beam line at the Photon Factory High Energy Accelerator Research Organization (KEK; Tsukuba, Japan) using a Pilatus3 2M detector at a sample-detector distance of 2 m and at a wavelength of λ = 0.15 nm (I(s) vs s, where s = 4πsinθ/λ, and 2θ is the scattering angle). In-line size-exclusion chromatography (SEC) SAS was employed. The SEC parameters were as follows: A 400.00 μl sample at 10 mg/ml was injected at a 0.20 ml/min flow rate onto a GE Superdex 200 Increase 10/300 column at 25°C. 13 successive 20 second frames were collected. The data were normalized to the intensity of the transmitted beam and radially averaged; the scattering of the solvent-blank was subtracted.",
"tags": [],
"intensity_unit": "1/cm",
"experimental_mw": 131.0,
"experimental_mw_error": null,
"guinier_i0_mw": 131.0,
"guinier_i0_mw_error": 0.2,
"porod_mw": 150.0,
"porod_mw_error": null,
"pddf_i0": 0.09482,
"pddf_i0_error": null,
"guinier_i0": 0.0956356,
"guinier_i0_error": null,
"pddf_rg": 4.17,
"pddf_rg_error": null,
"guinier_rg": 4.184,
"guinier_rg_error": 0.169,
"pddf_dmax": 12.85,
"pddf_dmax_error": null,
"porod_volume": 240.0,
"porod_volume_error": null,
"estimated_volume": null,
"estimated_volume_error": null,
"guinier_point_first": 60,
"guinier_point_last": 231,
"pddf_point_first": null,
"pddf_point_last": null,
"i0_calibration_standard_data": null,
"intensities_log_log_plot": "SASDW54_datloglog_img.png",
"symmetry": null,
"last_modified": "2025-03-17T16:06:56.010203+01:00",
"bragg_peak": []
}